Breaking News, Collaborations & Alliances

Merck Exercises Option for Cancer Vax Under Moderna Alliance

Merck to pay $250 million for personalized cancer vaccines including mRNA-4157/V940 and will collaborate on development and commercialization.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 under the terms of its existing Collaboration and License Agreement with Moderna. mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna.   Under the agreement established in 2016 and amended in 2018, Merck wi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters